Sarepta Therapeutics (NASDAQ:SRPT) Price Target Cut to $203.00 by Analysts at Barclays

Sarepta Therapeutics (NASDAQ:SRPT) had its price target lowered by Barclays from $226.00 to $203.00 in a report published on Thursday, Benzinga reports. The firm currently has an overweight rating on the biotechnology company’s stock.

Several other research firms have also recently commented on SRPT. Cantor Fitzgerald restated a neutral rating and set a $128.00 price target on shares of Sarepta Therapeutics in a research note on Friday, June 21st. Citigroup downgraded shares of Sarepta Therapeutics from a buy rating to a neutral rating and lifted their target price for the company from $172.00 to $176.00 in a report on Wednesday, June 26th. SVB Leerink increased their price target on shares of Sarepta Therapeutics from $165.00 to $230.00 and gave the stock an outperform rating in a report on Monday, June 24th. JPMorgan Chase & Co. reduced their price objective on shares of Sarepta Therapeutics from $177.00 to $175.00 and set an overweight rating for the company in a research report on Friday, May 3rd. Finally, Bank of America increased their target price on Sarepta Therapeutics from $166.00 to $213.00 and gave the stock a buy rating in a research note on Friday, June 21st. Three investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of Moderate Buy and an average target price of $186.22.

Sarepta Therapeutics Stock Performance

Shares of SRPT traded down $11.06 during midday trading on Thursday, reaching $125.34. 3,303,443 shares of the stock were exchanged, compared to its average volume of 1,396,233. Sarepta Therapeutics has a twelve month low of $55.25 and a twelve month high of $173.25. The company has a debt-to-equity ratio of 1.18, a current ratio of 4.05 and a quick ratio of 3.44. The company has a market capitalization of $11.85 billion, a price-to-earnings ratio of 1,139.45 and a beta of 0.89. The business’s 50-day moving average price is $140.91 and its 200 day moving average price is $131.44.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The company had revenue of $362.90 million for the quarter, compared to the consensus estimate of $394.38 million. During the same period last year, the firm posted ($0.27) EPS. Sarepta Therapeutics’s revenue for the quarter was up 38.9% on a year-over-year basis. On average, sell-side analysts expect that Sarepta Therapeutics will post 3.76 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Ryan Edward Brown sold 38,957 shares of the company’s stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $161.61, for a total value of $6,295,840.77. Following the sale, the executive vice president now directly owns 17,129 shares in the company, valued at $2,768,217.69. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Sarepta Therapeutics news, insider Bilal Arif sold 7,859 shares of the business’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $163.08, for a total value of $1,281,645.72. Following the completion of the transaction, the insider now directly owns 21,261 shares in the company, valued at approximately $3,467,243.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Ryan Edward Brown sold 38,957 shares of the firm’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $161.61, for a total value of $6,295,840.77. Following the completion of the sale, the executive vice president now directly owns 17,129 shares in the company, valued at $2,768,217.69. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by company insiders.

Institutional Trading of Sarepta Therapeutics

Institutional investors have recently made changes to their positions in the stock. Principal Securities Inc. purchased a new position in shares of Sarepta Therapeutics in the 4th quarter worth about $26,000. Mather Group LLC. purchased a new stake in Sarepta Therapeutics during the 1st quarter worth $28,000. Riggs Asset Managment Co. Inc. boosted its position in Sarepta Therapeutics by 125.0% in the 1st quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 125 shares during the last quarter. Innealta Capital LLC purchased a new stake in shares of Sarepta Therapeutics during the second quarter worth about $31,000. Finally, New Covenant Trust Company N.A. acquired a new position in shares of Sarepta Therapeutics in the first quarter worth about $32,000. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.